rheumatoid%20arthritis
RHEUMATOID ARTHRITIS

Rheumatoid arthritis is a systemic autoimmune rheumatic disorder of unknown etiology.
It is the most common form of inflammatory arthritis.
Patient usually complains of joint pain and/or swelling with morning stiffness that lasts for more than an hour.

Goals of treatment are clinical & radiological remission of disease and to reduce functional limitations & permanent joint damage.

  1. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010 Sep;69(9):1580-1588. doi: 10.1136/ard.2010.138461. PMID: 20699241
  2. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis. 2007 Nov;66(Suppl 3):iii2-iii22. PMID: 17934088
  3. Majithia V, Geraci SA. Rheumatoid arthritis: diagnosis and management. Am J Med. 2007 Nov;120(11):936-939. PMID: 17976416
  4. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011 Mar;63(3):573-586. doi: 10.1002/art.30129. PMID: 21294106
  5. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008 Jun;59(6):762-784. doi: 10.1002/art.23721. PMID: 18512708
  6. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010 Jun;69(6):964-975. doi: 10.1136/ard.2009.126532. PMID: 20444750
  7. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012 May;64(5):625-639. doi: 10.1002/acr.21641. PMID: 22473917
  8. National Institute for Health and Care Excellence. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor. NICE website. http://www.nice.org.uk/guidance/ta195/resources/guidance-adalimumab-etanercept-infliximab-rituximab-and-abatacept-for-the-treatment-of-rheumatoid-arthritis-after-the-failure-of-a-tnf-inhibitor-pdf. Aug 2010.
  9. National Institute for Health and Care Excellence. Adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. NICE website. http://www.nice.org.uk/guidance/ta130/resources/guidance-adalimumab-etanercept-and-infliximab-for-the-treatment-of-rheumatoid-arthritis-pdf. Sep 2010.
  10. National Institute for Health and Care Excellence. Abatacept for treating rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (rapid review of technology appraisal guidance 234). NICE website. http://www.nice.org.uk/nicemedia/live/14155/63676/63676.pdf. Apr 2013. Accessed 04 Jul 2013.
  11. Venables PJW, Maini RN. Clinical features of rheumatoid arthritis. UptoDate Web Site. http://www.uptodate.com/index. Feb 2011. Accessed 15 Apr 2011.
  12. National Institute for Health and Care Excellence. Certolizumab pegol for the treatment of rheumatoid arthritis. NICE website. http://www.nice.org.uk/guidance/ta186/resources/guidance-certolizumab-pegol-for-the-treatment-of-rheumatoid-arthritis-pdf. Feb 2010.
  13. UCB Pharma Inc. Certolizumab pegol: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125160s0142lbl.pdf. 2008. Accessed 05 Jul 2013
  14. Schur PH, Maini RN, Moreland LW. General principles of management of rheumatoid arthritis. UptoDate Web Site. http://www.uptodate.com/index. Feb 2011. Accessed 16 Apr 2011.
  15. Scottish Intercollegiate Guidelines Network. Management of early rheumatoid arthritis. SIGN. http://www.sign.ac.uk. Feb 2011. Accessed 15 Apr 2011
  16. Venables PJW, Maini RN. Diagnosis and differential diagnosis of rheumatoid arthritis. UptoDate Web Site. http://www.uptodate.com/index. Nov 2010. Accessed 15 Apr 2011.
  17. National Institute for Health and Care Excellence. Rheumatoid arthritis: the management of rheumatoid arthritis in adults. NICE website. http://www.nice.org.uk/guidance/cg79/resources/guidance-rheumatoid-arthritis-pdf. Feb 2009.
  18. Schur PH, Maini RN, Gibofsky A. Nonpharmacologic and preventive therapies of rheumatoid arthritis. UptoDate Web Site. http://www.uptodate.com/index. Dec 2010. Accessed 15 Apr 2011.
  19. National Institute for Health and Care Excellence. Tocilizumab for the treatment of rheumatoid arthritis. NICE website. http://www.nice.org.uk/guidance/ta198/resources/guidance-tocilizumab-for-the-treatment-of-rheumatoid-arthritis-pdf. Aug 2010.
  20. Smolen JS, Landewé R, Breedveld FC, Buch M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014 Mar;73(3):492-509. doi: 10.1136/annrheumdis-2013-204573. PMID: 24161836
  21. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2015 May. http://ard.bmj.com/content/early/2015/05/12/annrheumdis-2015-207524.full.pdf. PMID: 25969430
  22. Ritter J, Lewis L, Timothy M, Alberto F. Anti-inflammatory drugs and the treatment of arthritis. In: Hodder A. A Textbook in Clinical Pharmacology and Therapeutics. 5th ed. London, UK: Hodder Education; 2008:170.
  23. Singh JA, Saag KG, Bridges SL Jr, et al; American College of Rheumatology. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016 Jan;68(1):1-25. doi: 10.1002/acr.22783. PMID: 26545825
  24. McInnes IB. Cytokine networks in rheumatic diseases: Implications for therapy. UptoDate. http://www.uptodate.com. Aug 2018.
  25. Moreland LW, Cannella A. General principles of management of rheumatoid arthritis in adults. UptoDate. http://www.uptodate.com. May 2018.
  26. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016 Oct;388(10055):2023-2038. doi: 10.1016/S0140-6736(16)30173-8. PMID: 27156434
  27. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. PMID: 28264816
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
3 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
Yesterday
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 3 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.